The stocks Moderna flew up against positive tests of a vaccine from a cancer

The director general of Moderna declared that the experimental a melanoma vaccine of the company can become available by 2025. Shares of the company reacted rapid growth of the Photo: Shutterstock of the Action of the biotechnological company Moderna rose in price for 20,78%, to $94,93, at the NASDAQ exchange auction as of 17:43 Moscow time. Demand for papers grew against the message of the director general of Moderna Stephane Bansel that the experimental a melanoma vaccine of the company can become available in only two years. According to the director general, Moderna expects that in some countries the product can be...